Vandetanib is Used for treating symptomatic or progressive medullary thyroid cancer that is unresectable locally advanced or metastatic. It was first introduced by Genzyme Corp in its drug Caprelsa on Apr 6, 2011.

Vandetanib Patents

Given below is the list of patents protecting Vandetanib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Caprelsa	US7173038	Quinazoline derivatives as VEGF inhibitors	Aug 14, 2021 (Expired)	Genzyme Corp
Caprelsa	US8067427	Pharmaceutical compositions comprising ZD6474	Aug 08, 2028	Genzyme Corp
Caprelsa	US8642608	Quinazoline derivatives as VEGF inhibitors	Feb 06, 2022 (Expired)	Genzyme Corp
Caprelsa	USRE42353	Quinazoline derivatives and pharmaceutical compositions containing them	Sep 23, 2017 (Expired)	Genzyme Corp

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳